Amgen's denosumab misses in Phase III as adjuvant treatment for breast cancer

Amgen Inc. (NASDAQ:AMGN) and partner Daiichi Sankyo Co. Ltd. (Tokyo:4568) reported top-line data from the Phase III D-CARE trial in

Read the full 203 word article

User Sign In